ATI RN
Immune System Medication Questions
Question 1 of 5
A nurse is discussing interferon alfa 2b with a patient. What will the nurse encourage the patient to do while taking this drug?
Correct Answer: A
Rationale: The correct answer is A: To avoid crowds. Interferon alfa 2b can weaken the immune system, making the patient more susceptible to infections. Avoiding crowds helps reduce the risk of exposure to pathogens. B, increasing salt intake, is incorrect as it is not a recommended action for patients taking interferon alfa 2b. C, decreasing milk intake, is also incorrect as there is no evidence to suggest that milk consumption interferes with the effectiveness of this medication. D, eating three meals a day, is irrelevant to the action needed to manage the side effects of interferon alfa 2b.
Question 2 of 5
A patient has just been told that her cancer has metastasized to her right kidney. An interferon (Aldesleukin) has been prescribed to treat this metastasis. The patient asks why this interferon is ordered. What is the nurse's best response?
Correct Answer: B
Rationale: The correct answer is B: It activates human cellular immunity and inhibits tumor growth. Rationale: 1. Interferon (Aldesleukin) is known to activate the immune system, particularly cellular immunity. 2. By activating cellular immunity, interferon helps the body to recognize and attack tumor cells, inhibiting tumor growth. 3. This mechanism is crucial in fighting metastatic cancer, such as in the patient's case. 4. The other options are incorrect because interferon does not protect autologous tumor cells (A), enhance allogeneic stem-cell transplantation (C), or have a direct proliferative effect on renal tumors (D).
Question 3 of 5
The nursing class is studying monoclonal antibodies. What monoclonal antibody reacts to human T cells, disabling them and acting as an immune suppressor?
Correct Answer: D
Rationale: The correct answer is D, Muromonab-CD3. This monoclonal antibody specifically targets and reacts with human T cells, disabling them and acting as an immune suppressor. Muromonab-CD3 is used in conditions where T cells need to be suppressed, such as in transplant rejection. A: Adalimumab targets tumor necrosis factor-alpha, not T cells. B: Cetuximab targets epidermal growth factor receptor, not T cells. C: Rituximab targets CD20 antigen on B cells, not T cells.
Question 4 of 5
The nurse is caring for a patient with an allograft transplant. The physician orders a monoclonal antibody to prevent rejection of the transplant. What monoclonal antibody would the nurse expect to be ordered?
Correct Answer: B
Rationale: The correct answer is B: Daclizumab. Daclizumab is a monoclonal antibody that targets IL-2 receptors on T cells, preventing their activation and proliferation, thus reducing the risk of transplant rejection. Alemtuzumab (A) targets CD52 on T and B cells for leukemia treatment. Erlotinib (C) is a tyrosine kinase inhibitor for cancer. Omalizumab (D) targets IgE for allergic asthma.
Question 5 of 5
The nurse is caring for a female patient, aged 62, who has been admitted for treatment of metastatic melanoma. What agent would the nurse anticipate the physician is likely to order?
Correct Answer: D
Rationale: The correct answer is D: Ipilimumab. This drug is a checkpoint inhibitor used in the treatment of metastatic melanoma by enhancing the immune system to fight cancer cells. It is a common choice for this condition due to its effectiveness. Aldesleukin (A) and Interferon alfa 2b (B) are also immunotherapy agents but are not typically used as first-line treatments for metastatic melanoma. Cyclosporine (C) is an immunosuppressant used to prevent organ transplant rejection and manage autoimmune diseases, not for treating melanoma.